Mablink bags 31 million euros financing to advance ADC pipeline

Confirming that there are still plenty of investors ready to wager on attractive biotechnology prospects, France’s Mablink Biosciences today announced it has raised a 31 million-euro ($30 million) Series A funding round to advance its lead candidate to the clinic and to build a pipeline of antibody-drug conjugates (ADCs) using its proprietary platform technology.

The round was led by Sofinnova Partners and Mérieux Equity Partners, with participation from existing investors.

Lyon-based Mablink, which was founded in 2019, says its technology is based on a unique structure of chemical links (called “linkers”) placed between an antibody and any chosen cytotoxic molecule to be delivered into tumor cells. The unique structure of those linkers masks the cytotoxic molecule which provides a “stealthy” property to Mablink’s ADCs, conferring two highly desirable pharmacological properties.